Genetic strategies for the personalization of antipsychotic treatment

Expert Review of Molecular Diagnostics

Volumn 1, Issue 3, 2001, Pages 275-280

  Kerwin, Robert W ^a   Mancama, Dalu T ^a   Arranz, Maria J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic treatment; Individualisation of treatment; Pharmacogenetics

Indexed keywords

CYTOCHROME P450; NEUROLEPTIC AGENT;

DNA POLYMORPHISM; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; GENE MUTATION; GENETIC VARIABILITY; PHARMACOGENETICS; PSYCHIATRIC TREATMENT; REVIEW;

EID: 0035559856     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.1.3.275     Document Type: Review

References (48)

1. Pharmacogenetics for the individualization of psychiatric treatment
2. Molecular mechanisms of genetic polymorphisms of drug metabolism
3. The evolution of drug metabolism
4. Neurotransmitterrelated genes and antipsychotic response: Pharmacogenetics meets psychiatric treatment
5. Pharmacogenomics and schizophrenia
6. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility
7. 3 receptor and cytochrome P450 1A2 genes
8. Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders
9. Human cytochrome P450 (CYP) genes: Recommendations for the nomenclature of alleles
10. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain
11. Regiospecific expression of cytochrome P450s and microsomal epoxide hydrolase in human brain tissue
12. Rapid detection of the CYP2D6*3, CYP2D6*4 and CYP2D6*6 alleles by tetra-primer PCR and of the CYP3D6*5 allele by multiplex long PCR
13. Rapid and comprehensive determination of cytochrome P450CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction
14. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
15. Pharmacogenetics and adverse drug reactions
16. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
17. Antipsychotic drugs
18. The role of serotonin in antipsychotic drug action
19. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia
20. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene
21. 3 receptor gene with tardive dyskinesia in schizophrenia
22. 3 receptor and tardive dyskinesia in chronic schizophrenia
23. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
24. 3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients
25. 4 receptor 48-bp repeat polymorphisms: No association with response to antipsychotic treatment but association with catatonic schizophrenia
26. Association between clozapine response and allelic variation in the 5-HT2A receptor gene
27. Analysis of a structural polymorphism in the 5-HT 2A receptor and clinical response to clozapine
28. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
29. Association between clozapine response and allelic variation in the 5-HT2C receptor gene
30. Serotonin-6 receptor variant (C267T) and clinical response to clozapine
31. Replication and meta-analysis of alleleic association of a 5-HT2C receptor polymorphism with good response to clozapine
32. Application of pharmacogenetics to psychotic disorders: The first consensus conference
33. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
34. Pharmacogenetic prediction of clozapine response
35. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine Type 2a-receptor gene
36. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population
37. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia
38. Initial sequencing and analysis of the human genome
39. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
40. 3 receptor gene
41. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter
42. An MspI polymorphism in the hyman serotonin receptor gene (HTR2): Detection by DGGE and RFLP analysis
43. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia
44. Identification, expression and pharmacology of a Cys23-SeR23 substitution in the human 5-HT2c receptor gene (HTR2C)
45. Novel 5′-regulatory region polymorphisms of the 5-HT2C receptor gene: Association study with panic disorder
46. A novel functional polymorphism within the promoter of the serotonin transporter gene: Possible role in susceptibility to affective disorders
47. The histamine 1 and histamine 2 receptor genes-candidates for schizophrenia and clozapine response